1-(3-氨基-5-氯-2-羟基苯基)乙酮 | 21312-85-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(3-氨基-5-氯-2-羟基苯基)乙酮
• 英文名称: 3'-amino-5'-chloro-2'-hydroxyacetophenone
• 英文别名: 3-Amino-5-chlor-2-hydroxy-acetophenon；3-Amino-5-chloro-2-hydroxyacetophenone；1-(3-amino-5-chloro-2-hydroxyphenyl)ethanone
• CAS: 21312-85-6
• 化学式: C₈H₈ClNO₂
• mdl: MFCD11226218
• 分子量: 185.61
• InChiKey: ZTIGWUVHBVZOFX-UHFFFAOYSA-N

物化性质

• 熔点：
  110–112°C

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922509090

反应信息

• 作为反应物：
  描述：

  1-(3-氨基-5-氯-2-羟基苯基)乙酮 在 吡啶 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 生成 1H-Tetrazole-5-carboxylic acid (3-acetyl-5-chloro-2-hydroxy-phenyl)-amide
  参考文献：
  名称：

  Synthesis and quantitative structure-activity relationships of antiallergic 2-hydroxy-N-(1H-tetrazol-5-yl)benzamides and N-(2-hydroxyphenyl)-1H-tetrazole-5-carboxamides

  摘要：

  The synthesis and antiallergic activity of a series of 2-hydroxy-N-1H-tetrazol-5-ylbenzamides and isomeric N-(2-hydroxyphenyl)-1H-tetrazole-5-carboxamides is described. A relationship between structure and intravenous antiallergic activity in the rat passive cutaneous anaphylaxis (PCA) test has been established using a Hansch/Free-Wilson model and used to direct studies toward potent derivatives. The contribution of physicochemical properties to activity is discussed. One member of this series, N-(3-acetyl-5-fluoro-2-hydroxyphenyl)-1H-tetrazole-5-carboxamide (3f), which was selected for further evaluation, has an ID50 value of 0.16 mg/kg po and is 130 times more potent than disodium cromoglycate (DSCG) on intravenous administration.

  DOI：

  10.1021/jm00154a019

文献信息

• [EN] QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF<br/>[FR] DÉRIVÉS DE QUINAZOLINONES POUR LE TRAITEMENT DE LA STÉATOSE HÉPATIQUE NON ALCOOLIQUE, LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2022003712A1

  公开（公告）日：2022-01-06

  The present invention described herein relates to a compound having Structure I for treating diseases and disorders for which inhibition or modulation of the Ubiquitin Ligase COP1 enzyme produces a physiologically beneficial response, in particular for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD). These compounds having Structure I arecapable of increasing the level of adipose triglyceride lipase (ATGL). Also provided is the process of preparing compounds having Structure I.

  本发明描述了一种具有结构I的化合物，用于治疗通过抑制或调节泛素连接酶COP1酶产生生理上有益反应的疾病和紊乱，特别是用于治疗非酒精性脂肪肝病（NAFLD）。这些具有结构I的化合物能够增加脂肪三酸甘油酯脂解酶（ATGL）的水平。还提供了制备具有结构I的化合物的方法。
• PDE4 Inhibitor
  申请人：Meiji Seika Pharma Co., Ltd.

  公开号：US20160159783A1

  公开（公告）日：2016-06-09

  Provided is a compound represented by formula (1a) or a pharmacologically acceptable salt thereof. However, R 1 to R 6 in the formula each independently represent an alkyl group or the like.

  提供的化合物由式（1a）或其药学上可接受的盐表示。但是，在公式中，R1到R6各自独立地表示烷基或类似物。
• 2-Aminophenol derivatives, methods for their preparation and composition containing the same
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP0065874A1

  公开（公告）日：1982-12-01

  2-Aminophenol derivatives of general formula: [wherein R' represents a straight or branched chain alkyl group containing from 1 to 6 carbon atom(s), a group represented by general formula: (wherein R5 represents a hydrogen atom or a straight or branched chain alkyl group containing from 1 to 4 carbon atom(s) and n represents zero or an integer from 1 to 6) or a group represented by general formula: (wherein R6 represents a hydrogen atom, a halogen atom, a straight or branched chain alkyl group containing from 1 to 4 carbon atom(s), a straight or branched chain alkoxyl group containing from 1 to 4 carbon atom(s), a carbamoyl group, an alkoxycarbonyl group containing from 2 to 6 carbon atoms, a carboxyl group, an amino group, a sulfamoyl group or a cyano group and m represents zero or an integer of 1 or 2.), R2 represents a hydroxyl group, a straight or branched chain alkoxyl group containing from 1 to 4 carbon atom(s) or together with R3 an oxo group or a hydroxyimino group. R3 represents a hydrogen atom or together with R2 an oxo group or a hydroxyimino group. R° represents a halogen atom, a straight or branched chain alkyl group containing from 1 to 6 carbon atom(s) or a phenylthio group. With the exclusion of a compound wherein R2 and R3 taken together represent an oxo group, R' represents a methyl group and R4 represents a methyl group.] or their pharmaceutical acceptable acid addition salts which strongly inhibit 5-lipoxygenase specifically, or 5- lipoxygenase and cyclooxygenase at the same time, and are therefore useful as treating agents and preventing agents for diseases which are induced by leukotrienes e.g. allergic tracheal and bronchial diseases or allergic lung diseases, allergic shock and also various allergic inflammations which are induced by prostaglandins, and a process for their preparation and pharmaceutical compositions comprising them as active ingredients.

  通式如下的 2-氨基苯酚衍生物 [其中 R'代表含有 1 至 6 个碳原子的直链或支链烷基，由通式......代表的基团： (其中 R5 代表氢原子或含有 1 至 4 个碳原子的直链或支链烷基，n 代表零或 1 至 6 的整数）或通式：[其中 R6 代表氢原子或含有 1 至 4 个碳原子的直链或支链烷基，n 代表零或 1 至 6 的整数]所代表的基团： (其中 R6 代表氢原子、卤素原子、含 1 至 4 个碳原子的直链或支链烷基、含 1 至 4 个碳原子的直链或支链烷氧基、氨基甲酰基、含 2 至 6 个碳原子的烷氧羰基、羧基、氨基、氨基磺酰基或氰基，m 代表零或 1 或 2 的整数)，R2 代表羟基，R3 代表氢原子，R4 代表卤素原子。R2代表羟基、含有 1 至 4 个碳原子的直链或支链烷氧基，或与 R3 一起代表氧代基团或羟基亚氨基。R3 代表氢原子，或与 R2 一起代表一个氧代基团或羟基亚氨基基团。R° 代表卤素原子、含 1-6 个碳原子的直链或支链烷基或苯硫基。不包括 R2 和 R3 合在一起代表氧代基团、R'代表甲基和 R4 代表甲基的化合物]或其药物可接受的酸加成盐，它们能强烈抑制特定的 5-脂氧合酶，或同时抑制 5-脂氧合酶和环氧合酶，因此可用作白三烯诱导的疾病的治疗剂和预防剂，如过敏性气管炎和肺结核。例如过敏性气管和支气管疾病或过敏性肺部疾病、过敏性休克以及由前列腺素诱发的各种过敏性炎症，以及制备它们的工艺和含有它们作为活性成分的药物组合物。
• FORD, E.;KNOWLES, PH.;LUNT, E.;MARSHALL, S. M.;PENROSE, A. J.;RAMSDEN, A.+, J. MED. CHEM., 1986, 29, N 4, 538-549
  作者：FORD, E.、KNOWLES, PH.、LUNT, E.、MARSHALL, S. M.、PENROSE, A. J.、RAMSDEN, A.+

  DOI：——

  日期：——
• PROCESS FOR THE PREPARATION OF BENZOPYRAN COMPOUNDS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP0920427A1

  公开（公告）日：1999-06-09